Overview

B-PaLMZ for TB Meningitis

Status:
NOT_YET_RECRUITING

Trial end date:
2030-08-31

Target enrollment:

Participant gender:

Summary

This two-stage study will compare consented research participants with tuberculous meningitis receiving BPaLMZ to controls receiving SOC of rifampicin (R), isoniazid (H), pyrazinamide (Z), and ethambutol (E), known as RHZE.

Phase:

PHASE2

Details

Lead Sponsor:

University of Minnesota

Collaborator:

Infectious Diseases Institute